HTG Molecular Diagnostics, Inc. provided revenue guidance for full year 2022. For the period, total revenue is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | 0.00% | +66.67% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-14.50% | 19.69B | |
-39.00% | 3.01B | |
+22.02% | 1.94B | |
-0.62% | 1.66B | |
+35.90% | 1.34B | |
-22.01% | 895M | |
+5.89% | 827M | |
-23.80% | 638M | |
+10.85% | 516M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022